Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR).

MLA

Weber, Axel, et al. “Quantification of Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia (ALL) Using Amplicon-Fusion-Site Polymerase Chain Reaction (AFS-PCR).” Experimental Hematology & Oncology, vol. 1, no. 1, Nov. 2012, p. 33. EBSCOhost, https://doi.org/10.1186/2162-3619-1-33.

APA

Weber, A., Taube, S., Zur Stadt, U., Horstmann, M., Krohn, K., Bradtke, J., Teigler-Schlegel, A., Leiblein, S., & Christiansen, H. (2012). Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR). Experimental Hematology & Oncology, 1(1), 33. https://doi.org/10.1186/2162-3619-1-33

Chicago

Weber, Axel, Sylvia Taube, Udo Zur Stadt, Martin Horstmann, Knut Krohn, Jutta Bradtke, Andrea Teigler-Schlegel, Sabine Leiblein, and Holger Christiansen. 2012. “Quantification of Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia (ALL) Using Amplicon-Fusion-Site Polymerase Chain Reaction (AFS-PCR).” Experimental Hematology & Oncology 1 (1): 33. doi:10.1186/2162-3619-1-33.